Q
Consultant Live,
The US Food and Drug Administration (FDA) approved a label update for guselkumab (Tremfya) in May 2026, crediting the phase 3b…
Guselkumab (Tremfya) strengthens its case for protecting joints in psoriatic arthritis | 2 Minute Medicine
2 Minute Medicine ,
1. The FDA has expanded the label for guselkumab (Tremfya) to include evidence that it can inhibit progression of structural…
Artrite psoriasica: nuovi studi su terapia con guselkumab
corriere nazionale,
Nell’artrite psoriasica (PsA) la progressione del danno strutturale rappresenta un driver di disabilità e perdita di qualità di…
New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
BioSpace,
15 min read First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week 24, which was…